ArticleFrontiers in endocrinology2021
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m
Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Comprehensive Obesity Medicine Management in Metabolic and Bariatric Surgery (COMMMBS) Algorithm: An Evidenced Based Proposal.Obesity surgery · 2026Pooled it
- Migraine and Obesity: From Shared Mechanisms to Therapeutic Strategies.Neurology and therapy · 2026Review
- Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2025Article
- Adjuvant and Neo-Adjuvant Anti-Obesity Medications and Bariatric Surgery: A Scoping Review.Current obesity reports · 2024Article
- Estimating Type 2 Diabetes Prevalence: A Model of Drug Consumption Data.Pharmacy (Basel, Switzerland) · 2024Article
- Adipose tissue, systematic inflammation, and neurodegenerative diseases.Neural regeneration research · 2023Review
- Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities.Journal of enzyme inhibition and medicinal chemistry · 2022Review
- Preoperative Management with Mazindol for Obese Women Diagnosed with Endometrial Carcinoma Undergoing Robot-assisted Hysterectomy: A Pilot Case Series and Literature Review.Gynecology and minimally invasive therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the treatment of type 2 diabetes or seizures, respectively. The aim of the three cases is to demonstrate the clinical utility of topiramate and metformin for preoperative weight loss in patients with a body mass index (BMI) ≥ 50 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.